The World Anti-Doping Agency (WADA) added meldonium to its Prohibited List on January 1, 2016. This decision stemmed from research indicating its performance-enhancing effects, specifically regarding improved blood flow and oxygen utilization.
WADA’s rationale centered on meldonium’s ability to enhance athletic performance, giving athletes an unfair competitive advantage. This classification placed meldonium in the “hormone and metabolic modulators” category.
- The agency cited evidence suggesting meldonium’s use to mask other prohibited substances. WADA also considered the potential for cardiovascular benefits, translating to endurance enhancement.
Following the addition to the Prohibited List, WADA issued guidance to athletes regarding meldonium’s banned status. This included information on permissible use exemptions, testing procedures, and consequences for violations.
Athletes found with meldonium in their systems after January 1, 2016, faced sanctions, including potential bans from competition. The length of any ban depended on factors such as the concentration of meldonium detected and the athlete’s explanation for its presence. WADA acknowledged the challenges in determining the elimination period of meldonium from the body, particularly given individual variations in metabolism.
WADA’s approach to meldonium reflects its commitment to upholding fair play in sport and ensuring a level playing field for all athletes. The agency regularly reviews and updates its Prohibited List based on scientific evidence and expert consultation.
